Price
CHART BY
Frequently asked questions
What is Entrada's market capitalization?
The market capitalization of Entrada is $658.22M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Entrada's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Entrada is 11.04. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Entrada?
Entrada's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $1.594. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Entrada's stock?
Currently, 6 analysts cover Entrada's stock, with a consensus target price of $25.67. Analyst ratings provide insights into the stock's expected performance.
What is Entrada's revenue over the trailing twelve months?
Over the trailing twelve months, Entrada reported a revenue of $215.23M.
What is the EBITDA for Entrada?
Entrada's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $61.25M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Entrada?
Entrada has a free cash flow of -$17.46M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Entrada have, and what sector and industry does it belong to?
Entrada employs approximately 159 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Entrada's shares?
The free float of Entrada is 21.84M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $658.22M
- EPS (TTM)
- $1.594
- Free Float
- 21.84M
- P/E ratio (TTM)
- 11.04
- Revenue (TTM)
- $215.23M
- EBITDA (TTM)
- $61.25M
- Free Cashflow (TTM)
- -$17.46M
Pricing
- 52W span
- $11.40$21.77
Analyst Ratings
The price target is $25.67 and the stock is covered by 6 analysts.
Buy
6
Hold
0
Sell
0
Information
Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA.
- Employees
- 159
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US29384C1080
- Primary Ticker
- TRDA